A Way Forward for Cancer Chemoprevention: Think Local

被引:16
作者
Al Rabadi, Luai [1 ]
Bergan, Raymond [1 ]
机构
[1] Oregon Hlth & Sci Univ, Div Hematol Oncol, Knight Canc Inst, Portland, OR 97201 USA
关键词
ABERRANT CRYPT FOCI; BACILLUS-CALMETTE-GUERIN; HIGH-GRADE DYSPLASIA; CARCINOMA IN-SITU; CELL LUNG-CANCER; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CHEMOTHERAPY-NAIVE PATIENTS; 2.5-PERCENT HYALURONAN GEL; RANDOMIZED CLINICAL-TRIALS; IMIQUIMOD 5-PERCENT CREAM;
D O I
10.1158/1940-6207.CAPR-16-0194
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
As cells progress through carcinogenesis, the associated exponential expansion of genetic and molecular aberrations and resultant heterogeneity make therapeutic success increasingly unattainable. Therapeutic intervention at early stages of carcinogenesis that occurs within the primary organ and in the face of a lower burden of molecular aberrations, constitutes a basic tenet of cancer chemoprevention, and provides a situation that favors a greater degree of therapeutic efficacy compared with that of advanced cancer. A longstanding barrier to chemoprevention relates to the requirement for essentially no systemic toxicity, and the fact that when large numbers of people are treated, the emergence of systemic toxicity is almost universal. A rational means to address this in fact relates to a second basic tenet of the chemopreventive strategy: the focus of therapeutic intervention is to disrupt a process that is in essence localized to a single organ. Based upon this consideration, a strategy which is based upon local delivery of therapeutics to an at-risk organ will achieve therapeutic efficacy while avoiding systemic delivery and its associated toxicity. This article will review the rationale for undertaking such an approach, describe successful clinical achievements based on this strategy, describe ongoing efforts to expand the impact of this approach, and together will highlight the high impact that this approach has already had on the field as well as its extremely high potential for future impact. (C) 2016 AACR.
引用
收藏
页码:14 / 35
页数:22
相关论文
共 214 条
[1]
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening [J].
Aberle, Denise R. ;
Adams, Amanda M. ;
Berg, Christine D. ;
Black, William C. ;
Clapp, Jonathan D. ;
Fagerstrom, Richard M. ;
Gareen, Ilana F. ;
Gatsonis, Constantine ;
Marcus, Pamela M. ;
Sicks, JoRean D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (05) :395-409
[2]
Contrary view: The breast is not an organ per se, but distinctive region of skin and subcutaneous tissue [J].
Ackerman, A. Bernard ;
Kessler, Galen ;
Gyorfi, Tibor ;
Tsou, Hui C. ;
Gottlieb, Geoffrey J. .
AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2007, 29 (02) :211-218
[3]
Ackroyd R, 1999, PHOTOCHEM PHOTOBIOL, V70, P656, DOI 10.1562/0031-8655(1999)070<0656:AAPODB>2.3.CO
[4]
2
[5]
Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial [J].
Ackroyd, R ;
Brown, NJ ;
Davis, MF ;
Stephenson, TJ ;
Marcus, SL ;
Stoddard, CJ ;
Johnson, AG ;
Reed, MWR .
GUT, 2000, 47 (05) :612-617
[6]
Epidemiology of lung cancer [J].
Alberg, AJ ;
Samet, JM .
CHEST, 2003, 123 (01) :21S-49S
[7]
Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head [J].
Alomar, A. ;
Bichel, J. ;
McRae, S. .
BRITISH JOURNAL OF DERMATOLOGY, 2007, 157 (01) :133-141
[8]
Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
[9]
Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis [J].
Anderson, Lawrence ;
Schmieder, George J. ;
Werschler, W. Philip ;
Tschen, Eduardo H. ;
Ling, Mark R. ;
Stough, Dow B. ;
Katsamas, Janelle .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (06) :934-943
[10]
Anna Brozyna, 2007, Expert Rev Dermatol, V2, P451, DOI 10.1586/17469872.2.4.451